![]() |
Ponatinib Taken Off the Market...
December 1, 2013 - In the News / Politics By: Sherine Jaison, PharmD Candidate c/o 2015 – The leukemia chemotherapy drug ponatinib (Iclusig) has just been taken off the market. The drug was under investigation by the Food and Drug Administration (FDA) following several reports of serious and life threatening blood clots and narrowing of the blood vessels.1 Ponatinib is a BCR-ABL tyrosine kinase… |
![]() |
Hospital Drug Shortages...
December 1, 2013 - Featured , In the News / Politics By: Hamid Razaki, PharmD – Drug shortages seen across pharmacies in the United States continue to be an issue in patient care. A drug product shortage is defined as a supply issue that affects how the pharmacy prepares or dispenses a drug product, or that influences patient care when prescribers must use an alternative agent.1… |
![]() |
Still a Long Road Ahead for New Hepatitis C Treatment...
December 1, 2013 - In the News / Politics By: Ramya Mathew, PharmD Candidate c/o 2015 – Vertex Pharmaceuticals, an American biotechnology company based in Cambridge, Massachusetts, has been researching a new “nuke” for the treatment of Hepatitis C called VX-135. This nucleotide polymerase inhibitor is currently undergoing clinical trials, but the FDA has put the research on a partial hold due to findings… |
![]() |
Expanding a Technician’s Role...
December 1, 2013 - Professional Advice / Opinions By: Sang Hyo Kim, Staff Editor – Pharmacy, like much of medicine, is constantly changing, and the new changes in pharmacy practice are even happening to technicians. While there were originally no national standards for pharmacy-technician education and training, the American Society of Health-System Pharmacists (ASHP) and the Accreditation Council for Pharmacy Education (ACPE) have… |
![]() |
Provider Status for Pharmacists: Call to Action or Dist...
December 1, 2013 - Featured , In the News / Politics By: Samantha Schmidt, PharmD Candidate c/o 2014, Palm Beach Atlantic University – The role of pharmacists in healthcare has grown exponentially over the years. Pharmacists now provide advanced patient-centered care services including coordination of medications during transitions of care, comprehensive medication reviews with medication monitoring, chronic disease management, disease education, prevention and wellness services, and… |
![]() |
Zecuity(TM): Novel Treatment Option for Migraines...
November 1, 2013 - Clinical By: Arya Mathew, PharmD Candidate c/o 2014 – About twelve percent of the U.S. population suffers from migraines, affecting adult women three times more than adult men. Migraines are returning attacks of moderate to severe, throbbing or pulsing pain, usually on one side of the head. Along with the severe pain, migraine sufferers also experience… |
![]() |
Moving Towards Provider Status: An Interview with Sandr...
November 1, 2013 - Professional Advice / Opinions By: Hayeon Na, Co-Copy Editor and Sang Hyo Kim, Staff Editor – In Volume 1 Issue1 of the Rho Chi Post, we were honored to have an interview with Sandra Leal, PharmD, MPH, FAPhA, CDE, and Director of Clinical Pharmacy at El Rio Health Center in Tucson, Arizona. She had started a petition to support… |
![]() |
The Third Wheel or the Steering Wheel? Pharmacists on t...
November 1, 2013 - Professional Advice / Opinions By: Joshua Bliss, PharmD Candidate c/o 2016 – Doctor – a word often utilized by both professionals and the general public alike to describe a physician. “Doctor” finds its origins in the Latin word for “teacher.” The word “physician,” however, carries a more complicated origin. It is derived from Latin’s “physicum,” meaning remedy.1 In Luke… |
![]() |
Ceftriaxone Induced Hemolytic Anemia...
November 1, 2013 - Clinical , Featured By: Samad Tirmizi, PharmD Candidate c/o 2014 – Hemolytic anemia (HA) is a type of anemia that occurs due to the breakdown of red blood cells. It is classified as intrinsic and extrinsic according to causative factors. Medication induced hemolytic anemia is an example of extrinsic, while genetic predisposition is an intrinsic factor. Drug induced… |
![]() |
New Treatment for a Deficiency in Iron-Supplement Thera...
October 1, 2013 - Clinical By: Davidta Brown, Staff Editor – For the estimated 7.5 million individuals in the United States living with iron deficiency anemia (IDA), there is now a new alternative to iron supplements or time-consuming, repetitive infusions. On July 25, 2013, the FDA approved ferric carboxymaltose injection (Injectafer®) for the treatment of IDA, especially in patients who… |
![]() |
New Drug to Treat HIV-1 Hits the Market...
October 1, 2013 - Clinical , Featured By: Ada Seldin, Staff Editor – On August 12,2013, a new weapon against HIV-1 infection was added to the existing armada. Dolutegravir, the third integrase strand transfer inhibitor to attain FDA approval, targets a protein essential to HIV replication. HIV-1 is the predominant type of HIV virus, the other being HIV-2, which is endogenous to… |
![]() |
After 15 Years, First New Recombinant Coagulation Facto...
October 1, 2013 - Clinical By: Tamara Yunusova, Senior Staff Editor – After a lengthy fifteen-year hiatus in recombinant drug approvals, FDA-approved Recombinant Coagulation Factor IX (Rixubis) has mounted to the forefront of Hemophilia B drug therapy. The recombinant coagulation factor gained orphan drug approval on June 26, 2013 for routine prophylaxis, control of bleeding episodes, and perioperative management in… |
![]() |
Ketoconazole No More...
October 1, 2013 - Featured , In the News / Politics By: Hayeon Na, Co-Copy Editor [Content-Focused] – The Food and Drug Administration (FDA) announced on July 26th that oral dosage forms of ketoconazole (Nizoral®) should no longer be prescribed as first-line therapy for any fungal infections.1 The label and indication for oral ketoconazole were updated, and a new medication guide was added. Other dosage forms… |
![]() |
Canagliflozin (Invokana®): New Type 2 Diabetes Drug...
October 1, 2013 - Clinical By: Sang Hyo Kim, Staff Editor – On March 29th 2013, the U.S Food and Drug Administration approved canagliflozin (Invokana®), a new form of a diabetic drug for patients with type 2 diabetes mellitus.1 Canagliflozin is in a new class of medications called sodium glucose co-transporter 2 (SGLT2) inhibitors and is the only oral, once-daily… |
![]() |
Nattokinase use in DVT prophylaxis...
October 1, 2013 - Clinical Samad Tirmizi, Pharm. D. Candidate c/o 2014 – Deep vein thrombosis (DVT) is a clot formation that occurs within deep veins, generally in the legs. This can cause swelling and pain due to the engorged vessels, and can eventually result in further complications such as a pulmonary embolism. Patients at high risk for DVT are… |
![]() |
An Interview with Dr. Barile: Professor, Reseacher, and...
September 1, 2013 - Professional Advice / Opinions By: Katharine Cimmino, Editor-in-Chief & Bharat Kirthivasan, Co-Copy Editor – Frank A. Barile Ph.D. is a Professor of Clinical and Applied Toxicology at St. John’s University. He is also a St. John’s University alumnus, having received a B.S. in Pharmaceutical Science, an M.S. in Toxicology, and a Ph.D. in Pharmacology. At St. John’s University, Dr.… |
![]() |
FDA’s New Warning: Acetaminophen Associated with Seri...
September 1, 2013 - Featured , In the News / Politics By: Andy Zhang, PharmD Candidate c/o 2015 – On August 1st, 2013, the U.S. Food and Drug Administration (FDA) released a new warning of serious acetaminophen associated skin reactions, including Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN) and acute generalized exanthematous pustulosis (AGEP).1 Acetaminophen is one of the most widely used over-the-counter (OTC) medication, and… |
![]() |
Olmesartan Medoxomil Label Revision...
September 1, 2013 - In the News / Politics By: David Ong, PharmD Candidate c/o 2014 – Manipulating the renin-angiotensin system is one of the many ways drugs are used to treat hypertension. By blocking key steps in the renin-angiotensin cascade, blood pressure decrease may be achieved. Angiotensin II receptor blockers (ARBs) represent one of the drug classes that utilize the aforementioned mechanism. ARBs… |
![]() |
HIV Test: Making a Difference...
September 1, 2013 - In the News / Politics By: Sang Hyo Kim, Staff Editor – On June 27, 2013, the Centers for Disease Control and Prevention (CDC), AIDS.gov, and other national and local entities organized the 19th annual National HIV Testing Day. On this day, the theme of “Take the Test, Take Control” was employed to spread awareness of testing and prevention methods… |
![]() |
Children, Codeine, and Cytochrome P-450...
September 1, 2013 - Clinical , Featured By Davidta Brown, Staff Editor – For post-operative pain treatment, few drugs are as trustworthy, as tried-and-true, as codeine. Prescriptive confidence in the analgesic has promoted its use in children recovering from uncomplicated surgeries, but the spate of injuries and deaths of young children who had been given codeine after undergoing adenotonsillectomies has provoked a… |
![]() |
A Close Concurrence on Certolizumab (Cimzia®)...
September 1, 2013 - Clinical , Featured By: Sang Hyo Kim, Staff Editor – This year, on July 23rd, FDA advisers voted 7 to 6, with one abstention, in favor of approving the drug certolizumab (Cimzia®) for the indication of axial spondyloarthritis (axSpA). axSpA is a chronic imflammatory condition that includes ankylosing spondylitis (AS) and non-radiographic axial spndyloarthristis (nr-axSpA).1,2 axSpA, AS and… |
![]() |
New Findings Regarding Cardiovascular Adverse Events wi...
August 1, 2013 - Clinical , Featured By: Aleena Cherian, Co-Copy Editor [Graphics-Focused] – Attention deficit/hyperactivity disorder (ADHD) is a chronic neurological behavior characterized by persistent patterns of inattention and/or hyperactive behavior, resulting in a wide range of emotional, functional, and neurocognitive impairments.1,2 First line therapy for ADHD consists of stimulant medications together with non-pharmacologic interventions, and has been shown to improve… |
![]() |
Comparison of the New Oral Antithrombotics and Warfarin...
August 1, 2013 - Clinical , Featured By Omar Khalid Pharm.D. Candidate c/o 2014 – The outpour of a multitude of new oral anticoagulants in recent years has health care professionals questioning whether they should switch the patients over, and what new agents should be used. With the recent addition of dabigatran (Pradaxa®) in October 2010, rivaroxaban (Xarelto®) in November 2011, and… |
![]() |
DIA 2013 Annual Meeting: Boston, Massachusetts...
August 1, 2013 - Events By: Kristin M. Cheng, PharmD candidate c/o 2014 – The Drug Information Association (DIA) 2013 Annual Meeting took place from June 23rd to June 27th at the Boston Convention and Exhibition Center in Boston, Massachusetts. Twenty-one students from the St. John’s University DIA student chapter attended this year. The purpose of the meeting was… |
![]() |
Two New Agents for the Treatment of Obesity...
August 1, 2013 - Clinical , Featured By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU – Obesity is defined as having a body mass index (BMI) of 30 kg/m2 or greater. It is thought to be the result of an imbalance between energy intake and energy expenditure, possibly due to a number of genetic and environmental factors.1 It is estimated… |
![]() |
Superbug Makes Super Waves in Hospitals Across America...
July 1, 2013 - In the News / Politics By: Beatrisa Popovitz, Staff Editor – For the past decade, antibiotic resistant bacteria have been a growing concern in healthcare. Over the last few months, there has been a great deal of media attention surrounding strains of drug resistant bacteria in hospitals across the United States. Most recently, there has been an increased effort to… |
![]() |
Understanding Opioid Overdose...
July 1, 2013 - Clinical , Featured By: Aleena Cherian, PharmD Candidate c/o 2014 – Although opioid analgesics are among the most effective drugs to treat pain, they are associated with a growing number of public health issues including addiction and severe, often fatal, overdoses. The recent increase in incidences of opioid overdose is directly correlated to rapidly increasing and widespread use… |
![]() |
Solving the HCV Enigma: Current and Future Drug Therapy...
July 1, 2013 - Clinical , Featured By: Tamara Yunusova, Senior Staff Editor – Approximately 3.2 million Americans have chronic hepatitis C infection.1 While acute cases are not common, rates of chronic hepatitis C continue to surge due to the recent discovery of the virus in 1989 and consequently, the establishment of a test screening for HCV antibodies in 1992.1 HCV has… |
![]() |
Compounding at a Crossroads: New Boundaries in the Afte...
July 1, 2013 - Featured , In the News / Politics Davidta Brown, PharmD Candidate c/o 2017 – The debate on the nature of compounding practice and the extent to which it ought to be regulated has come to the forefront of public attention. Those who regularly follow American news and politics are familiar with the series of events that have led to the present… |
![]() |
PSSNY Convention...
July 1, 2013 - Events By Taryn Mondiello, PharmD Candidate c/o 2015 – From June 7th to June 9th, pharmacists from all over New York State gathered at the LaGuardia Marriott in East Elmhurst for the 135th annual PSSNY summer convention. The Pharmacists Society of the State of New York, better known as PSSNY, was founded in 1879 and is… |
![]() |
FDA Takes Major Strides Towards Opioid Abuse Prevention...
June 1, 2013 - Featured , In the News / Politics By: Ada Seldin PharmD Candidate c/o 2015 – On April 16th, 2013, the FDA approved the labeling change for the reformulated OxyContin® (oxycodone hydrochloride controlled-release) tablets, made by Pharma L.P. This change reflects the abuse-deterrent properties of the reformulated OxyContin®, which were not present in the original formulation approved by the FDA in 1995. OxyContin®… |
![]() |
Coffeehouse Chats...
June 1, 2013 - Events By: Ada Seldin and Moisey Rafailov, PharmD Candidates Class of 2015 – The “Coffeehouse Chats” is an annual Rho Chi Society Event that serves as a steppingstone to fostering professional relationships between students and faculty. The event provides a platform for students and professors to exchange experiences and ideas. This year, the event took place… |
![]() |
Helping Solve the Cruel Mystery...
June 1, 2013 - Featured , In the News / Politics By: Erica Dimitropoulos, Senior Staff Editor – Lupus is highly unpredictable and occurs without warning; there is no known cause and no known cure. It affects over 1.5 million Americans, 90% of whom are women between the ages of 15 – 44.1 No two cases of lupus are alike, making it a very difficult disease… |
![]() |
Pay to Delay: The Honest Truth...
June 1, 2013 - Professional Advice / Opinions By: David Ong, Pharm.D. Candidate c/o 2014 – Our current healthcare system receives much criticism from the press as well as the public. Big pharmaceutical companies (“Big Pharma”) have consistently been characterized as part of the problem. Most of the blame for high drug costs is levied on Big Pharma. One of the criticisms is… |
![]() |
FDA Approves Dimethyl Fumarate for Treatment of Relapsi...
June 1, 2013 - Clinical , Featured By: Andy Zhang, PharmD Candidate c/o 2015 – On March 28, 2013, the U.S. Food and Drug Administration announced the approval of Tecfidera™ (dimethyl fumarate) for the treatment of relapsing forms of multiple sclerosis (MS) in adults.1 Tecfidera™ (dimethyl fumarate) will be the third oral drug used for the treatment of MS. The manufacturer Biogen… |
![]() |
Noninvasive Cancer Screening—Will We Ever Get It Righ...
June 1, 2013 - Clinical , Featured By: Frances Sousonis, Candidate c/o 2017 – Unfortunately, cancer is a disease about which many are able to share stories. All too often, beloved persons are diagnosed with cancer, or, more regrettably, loses their battle with the beast. Colon cancer is the third most common cancer in the United States and around 150,000 people each… |
![]() |
Disclosure of Clinical Research Funding: Can Ignorance ...
May 1, 2013 - Professional Advice / Opinions By: Bharat Kirthivasan, Co-Copy Editor [Content-Focused] – Most people would prefer that a research paper be mandated to disclose its source of funds. For example, if a publication effusively supports a certain drug, we want to know if its parent company is footing the bill. Transparency allows research to be viewed in light of its… |
![]() |
Regulation of Low to Moderate Risk Medical Devices by t...
May 1, 2013 - Featured , Professional Advice / Opinions By: Hayeon Na, Co-Copy Editor [Content-Focused] – On March 22, 2013, Public Broadcasting Service (PBS) aired an episode of “Need to Know” on the safety of low to moderate risk medical devices. The episode closely followed the lawsuit of patient Linda Gross who has pelvic organ prolapse and was advised by her doctor to undergo… |
![]() |
Event Review: Pharmacy Day...
May 1, 2013 - Events By: Helen Dong, PharmD Candidate c/o 2014 – Pharmacy Day, or Legislative Day, is a whole day affair for pharmacy students to meet and speak to members of the federal and state legislature in order to discuss issues that affect pharmacists and to lobby for our profession. This year’s talking points were expanding immunization rights… |
![]() |
Can a Pharmacist Prevent the Next Pileup?...
May 1, 2013 - Clinical By: Moisey Rafailov, PharmD Candidate c/o 2015 – It was early in the morning on New York’s Route 684 when a car hit a tractor-trailer and continued driving without regard. Imagine that, when later stopped by a police officer, the driver said that the accident was her pharmacist’s fault. What if I were to tell… |
![]() |
Alzheimer’s Disease On The Rise...
May 1, 2013 - Clinical , Featured By: Ada Seldin – An impending storm is threatening to stagger the health care system and the nation at large. Alzheimer’s disease, which now affects as many as 5.1 million Americans, is projected to triple its toll by 2050, to 13.8 million Americans.1 These sky-rocketing rates can be attributed to aging of the ‘baby boomers.’2… |
![]() |
AUVI-Q™: The Newest Epinephrine Device to Hit the Mar...
May 1, 2013 - In the News / Politics By: Diana Gritsenko, Pharm D. Candidate c/o 2015 – Most of us who work in a community pharmacy setting will usually get a few scripts a month for an Epi-pen™. An Epi-pen™ is a device that autoinjects epinephrine (also known as adrenaline) into a patient who is experiencing anaphylaxis. Anaphylaxis is a severe, whole-body allergic… |
![]() |
Plan B® Pill Now Available Without Prescription to Wom...
May 1, 2013 - Featured , In the News / Politics By: Bansri Patel – As of May 1st 2013, Plan B®, the brand name emergency contraception pill will now be available to women aged fifteen and older. It will also be sold in the drug store aisles, as opposed to its current location behind the pharmacy counter. When levonorgestrel (Plan B®) first entered the market,… |
![]() |
FDA Approves New Drug ‘Tofacitinib’ for Rheumatoid ...
April 1, 2013 - Clinical , Featured By: Erica Dimitropoulos, Senior Staff Editor – Rheumatoid arthritis is a painful and often debilitating autoimmune disease characterized by symmetric polyarthritis, most commonly of the proximal interphalangeal and metacarpophalangeal joints, elbows, knees, ankles, and spine.1 Its clinical manifestations vary, from a slowly progressing onset of fatigue and musculoskeletal discomfort to a sudden and worsening destruction… |
![]() |
Breaking the Mold...
April 1, 2013 - Professional Advice / Opinions By Beatrisa Popovitz, Staff Editor, Why does that pharmacist have to be two and a half feet higher than everybody else? Who the hell is this guy? “Clear out everybody I’m workin’ with pills up here. I’m taking pills from this big bottle and then I’m gonna put them in a little bottle! That’s my… |
![]() |
Merck Settles Lawsuits Over Vytorin...
April 1, 2013 - In the News / Politics By: Tasnima Nabi, Staff Editor – Merck & Co. will pay $688 million to settle two lawsuits filed in December 2008 over their patent-protected statin, Vytorin®. The suits state that Merck and Schering-Plough delayed releasing the results of their ENHANCE study to avoid a decrease in revenue.1 Vytorin® is a combination drug of simvastatin and… |
![]() |
Flu Season 2012-2013: Rising Opportunities for Pharmaci...
April 1, 2013 - Clinical By: Fawad Piracha, Pharm. D Candidate c/o 2016 – The 2012-2013 influenza season has developed into one of the greatest nationwide flu outbreaksof the decade.1 Amid this crisis, many flocked to healthcare providers with flu-like symptoms, while others scoured doctors’ offices, clinics, and pharmacies for the vaccine. With the flu claiming many lives throughout the… |
![]() |
Pharmaceutical Industry: More than One Way In...
April 1, 2013 - Events By: David Ong, Pharm.D. Candidate c/o 2014 – There are many research opportunities available for pharmacists after graduation. However, most pharmacy students do not know enough about these opportunities as they progress through pharmacy school. Jason Lee, a guest speaker at the monthly Drug Information Association meeting, explained the different aspects of industry and industry… |
![]() |
Increased Costs of Treatment due to the DSM-V: Implicat...
April 1, 2013 - Featured , In the News / Politics By: James W. Schurr and David Gao, PharmD Candidates 2014 – A recent Op-ed in Newsday by Allen Frances, MD (of Duke University School of Medicine and chairman of the task force that produced the DSM-IV, the current guidelines for psychiatric disease diagnosis) criticizes the American Psychiatric Association for being “extravagantly indifferent to all matters… |
![]() |
Documentation of Drug Allergies in Hospitalized Older A...
April 1, 2013 - Clinical , Featured By: Nandini Puranprashad, PharmD Candidate; Sibyl Cherian, PharmD Candidate; Tracey Cannova, PharmD Candidate; and Olga HilasPharmD, MPH, BCPS, CGP – Adverse drug reactions are estimated to occur in 10-20% of hospitalized patients and in 7% of the general population.1 One-third of these reactions are of an allergic or pseudo-allergic nature. The consequences of these hypersensitivity… |